Autologous Immune Cell Therapy in Combination With LHRH-a in Patients With mCRPC

Inclusion Criteria:

* Males age ≥ 18 years；
* Subjects who understand and sign the consent form for this study；
* Metastatic， castrate resistant, histologically confirmed prostate cancer；
* PSA\> 5ng / ml；
* Serum testosterone ≤ 17nmol / L (50ng / dl)；
* Expected survival time of at least 24 months；
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1；
* Subjects did not receive chemotherapy, radiation therapy, surgery and other treatment within 4 weeks；

Exclusion Criteria:

* The subject has an allergic history of medicine or food；
* The patient with more serious heart disease, including but not limited to myocardial infarction, cardiomyopathy, valvular disease, malignant arrhythmia；
* Hb \<9.0 g / 100ml, WBC \<3 ×10\^9/ L, LY \<1.0 x10\^9/ L, platelet \<100,000 / mm3；
* Patients with immune disease or auto-immune disease (such as Multiple sclerosis, systemic lupus erythematosus，rheumatoid arthritis and inflammatory bowel disease, vitiligo )；
* The subject has uncontrolled or hard-to-control diseases of liver, or kidney system；
* Patient with visceral metastases, pathological fractures, spinal cord compression symptoms；
* Severe pain associated with bone metastases (VAS score ≧ 4 points)；
* Patient has received immunotherapy (including but not limited to PD-1 / PDL-1, etc.)；
* patient with irregular hemorrhagic disease；
* Subject is HIV, hepatitis B virus, hepatitis C virus, Treponema pallidum infection；
* Subject has uncontrollable seizures, or because of mental loss of self-knowledge and so on；
* The subject has an history of other malignant tumor；
* The patient had drug abuse, drug abuse, and long history of alcoholism in the 12 years prior to this trial；
* The subject has participated in any other clinical trial in the 3 months prior to this trial；
* The subject has any other unsuitable or adverse condition to be determined by the investigator.